Replies to post #152266 on Biotech Values

[DewDiligence]

SNY’s 50% price cut of Zaltrap won’t help patients (unless they are self-pay):

http://blogs.scientificamerican.com/guest-blog/2012/11/19/why-sanofis-zaltrap-deal-wont-help-patients/